Elevated C-reactive protein levels in the development of type 1 diabetes

Diabetes

Volumn 53, Issue 10, 2004, Pages 2569-2573

  Chase, H Peter ^a,c   Cooper, Sonia ^a   Osberg, Iris ^b   Stene, Lars C ^a,d   Barriga, Katherine ^b   Norris, Jill ^b   Eisenbarth, George S ^a   Rewers, Marian ^a,b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Division of Epidemiology ^*  (United States)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PANCREAS ISLET AUTOANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL STUDY; CONTROLLED STUDY; DIABETES AUTOIMMUNITY STUDY OF THE YOUNG; DIABETOGENESIS; ENZYME IMMUNOASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

AUTOANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; INFLAMMATION; PREDIABETIC STATE; REPRODUCIBILITY OF RESULTS;

EID: 4644312912     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.10.2569     Document Type: Article

References (23)

1. Pradhan A, Manson J, Rifai N, Buring J, Ridker P: C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
2. Pickup J, Crook A: Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
3. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R: First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 26:819-824, 2003
4. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42-47, 2000
5. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H: The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, and systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 27:443-449, 2003
6. Pieroni L, Bastard J, Piton A, Khalil L, Hainque B, Jardel C: Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 29:133-138, 2003
7. Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Small M: Determinants of raised C-reactive protein concentration in type 1 diabetes. Q J Med 93:231-236, 2000
8. Schalkwijk CG, Poland DCW, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VWM, Stehouwer CDA: Plasma concentration of C-reactive protein is increased in type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351-357, 1999
9. Chase HP, Williams RL, Dupont J: Increased prostaglandin synthesis in childhood diabetes mellitus. J Pediatr 94:185-189, 1979
10. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She J-X, Hofig A, Dennis MA, Fuller K, Cook R, Schatz D, Moldawer LL, Clare-Salzler MK: Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 104:515-552, 1999
11. Litherland SA, She J-X, Schatz D, Fuller K, Hutson AD, Peng RH, Li Y, Grebe KM, Whittaker DS, Bahjat K, Hopkins D, Fang Q, Spies PD, North K, Wasserfall C, Cook R, Dennis MA, Crockett S, Sleasman J, Kocher J, Muir A, Silverstein J, Atkinson M, Clare-Salzler MJ: Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. Pediatr Diabetes 4:10-18, 2003
12. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1988. Arch Intern Med 13:93-99, 2003
13. Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229, 2001
14. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffle RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 39:807-812, 1996
15. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase HP, Klingensmith G, Erlich H, Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264-4267, 1996
16. Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 97:1701-1706, 2000
17. Bingley PJ, Bonifacio E, Mueller PW: Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 52:1128-1136, 2002
18. SAS Institute: SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC, SAS Institute, 1997
19. Targher G, Zenari L, Bertoloini L, Muggeo M, Zoppini G: Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications (Letter). Diabetes Care 24:956-957, 2001
20. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC: Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78:273-277, 1997
21. Hundal R, Petersen K, Mayerson A, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321-1326, 2002
22. Bohmer KP, Kolb H, Kuglin B, Zielasek J, Hubinger A, Lampeter EF, Weber B, Kolb-Bachofen V, Jastram HU, Bertrams J, Gries FA: Linear loss of insulin secretory capacity during the last 6 months preceding IDDM. Diabetes Care 17:138-141, 1994
23. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 70:560S-569S, 1999